AI-created image
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:David_Lucchino
|
| gptkbp:clinicalTrialPhase |
gptkb:FX-322_Phase_2a
|
| gptkbp:collaboratedWith |
gptkb:Astellas_Pharma
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
small molecule drugs
|
| gptkbp:focusesOn |
regenerative medicine
hearing loss treatment |
| gptkbp:foundedIn |
2014
|
| gptkbp:founder |
gptkb:Jeffrey_Karp
gptkb:Robert_S._Langer |
| gptkbp:headquartersLocation |
gptkb:Lexington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Frequency Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:FX-322
|
| gptkbp:platform |
progenitor cell activation
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:FREQ
|
| gptkbp:website |
https://www.frequencytx.com/
|
| gptkbp:bfsParent |
gptkb:Robert_Langer
|
| gptkbp:bfsLayer |
3
|